AOD-9604 Renal Protection or Renal Risk: What the Evidence Actually Shows

What Is AOD-9604 and Why Does the Kidney Question Matter?

AOD-9604 is a synthetic peptide comprising amino acids 176 through 191 of the C-terminal region of human growth hormone. Researchers isolated this fragment because full-length GH drives lipolysis partly through a receptor-independent mechanism localized to that terminal segment. The kidney question matters because full-length GH is a well-documented driver of glomerular hyperfiltration, mesangial expansion, and proteinuria, particularly in patients with diabetes or pre-existing chronic kidney disease (CKD). [1]

If AOD-9604 retains GH's lipolytic activity without activating the GH receptor, the theoretical renal risk profile differs substantially from that of GH itself. Whether that theoretical difference translates into genuine renal safety, or into any protective effect, remains unresolved.

The Growth Hormone Receptor and Kidney Disease

Full-length GH signals through the GH receptor (GHR), triggering JAK2/STAT5 phosphorylation. In the kidney, GHR is expressed in glomerular mesangial cells, proximal tubule epithelium, and collecting duct cells. [2] Sustained GHR activation raises IGF-1 locally and systemically, and IGF-1 in turn promotes glomerular hypertrophy, increases single-nephron GFR, and accelerates diabetic nephropathy progression. [3]

A 2003 analysis in Kidney International confirmed that GH excess states, including acromegaly, produce measurable increases in kidney volume and creatinine clearance, followed by proteinuria and fibrosis over time. [4] That mechanistic chain is the core reason any GH-related peptide requires renal scrutiny before broad clinical use.

Where AOD-9604 Differs Mechanistically

Heffernan et al. Published the foundational pharmacology study in Endocrinology in 2001 (N = obese mice and lean controls). [1] The study demonstrated that AOD-9604 administered at 500 mcg/kg intraperitoneally reduced body fat in obese mice by approximately 50% over 14 days without elevating IGF-1 levels, without stimulating tibial growth plate width (a surrogate for GHR activation), and without altering fasting glucose. Lean animals showed no change in body composition.

That mechanistic dissociation, lipolysis without GHR activation, is the pharmacological argument against GH-type renal stress. It is not, however, evidence of renal protection.

Preclinical Renal Data: What Animal Studies Can and Cannot Tell Us

No published study has specifically examined AOD-9604 renal histology, glomerular filtration rate, or tubular function in animals as a primary endpoint. The absence of published renal data is itself a data point that clinicians should weigh.

Lessons From Structurally Similar Peptides

Research on other C-terminal GH fragments provides partial context. A 1996 study by Ng et al. In Molecular and Cellular Endocrinology showed that GH fragments lacking the receptor-binding domain did not reproduce the renal hypertrophy seen with intact GH in hypophysectomized rats. [5] That finding supports the mechanistic inference that AOD-9604 is unlikely to drive glomerular hypertrophy through the same pathway as full-length GH, but the two peptides differ in sequence length and tertiary structure.

IGF-1 and the Renal Axis

Because AOD-9604 does not raise IGF-1 (per Heffernan 2001 [1]), the IGF-1-mediated renal growth pathway should remain quiescent. IGF-1 receptor activation in proximal tubule cells stimulates sodium reabsorption and increases GFR; chronically elevated IGF-1 is associated with a 1.4-fold increase in incident microalbuminuria in population cohorts followed over five years. [6] Suppressing that axis is not the same as actively protecting the kidney, but it removes a known hazard.

Oxidative Stress and Tubular Injury

A secondary preclinical question concerns whether AOD-9604 or its metabolic breakdown products exert direct tubulotoxicity. Peptides cleared primarily by renal tubular catabolism can accumulate in proximal tubule cells when GFR falls. The molecular weight of AOD-9604 is approximately 1,815 daltons. Peptides in the 1,000 to 5,000 dalton range are generally filtered freely at the glomerulus and degraded by brush-border peptidases and lysosomal enzymes in the proximal tubule. [7] No published data characterize AOD-9604's tubular handling specifically.

Human Clinical Data: The Honest Accounting

The human evidence base for AOD-9604 is thin. Metabolic Pharmaceuticals conducted Phase I and Phase II trials between 1998 and 2005 under the trade name Tregopil (not to be confused with the insulin analog of the same name marketed later). Those trials focused on body weight and metabolic endpoints; renal function was not a primary or secondary endpoint in the available published abstracts.

The Australian Therapeutic Goods Administration reviewed AOD-9604 and rejected its application for obesity in 2006, partly on insufficient efficacy data. No NDA has been submitted to or approved by the FDA. [8]

The 503A Compounding Context

In the United States, AOD-9604 is currently dispensed through 503A compounding pharmacies under prescriber order. The FDA's guidance on compounded peptides does not confer approved-drug status, and compounded preparations are not subject to the same manufacturing quality standards as NDA-approved drugs. [8] Variability in purity, peptide folding, and excipient content across compounders introduces an additional layer of uncertainty for any organ-specific safety assessment.

The FDA's 2023 guidance on bulk drug substances for compounding notes that a drug substance may be placed on the 503A bulks list only after a formal evaluation of whether it presents "risks" that outweigh clinical need. AOD-9604 was nominated for that list; as of July 2025, the agency has not published a final determination. [8]

What Phase II Metabolic Data Show

A 24-week randomized controlled trial of oral AOD-9604 (1 mg/day) in 300 obese adults, referenced in Metabolic Pharmaceuticals' investor documents but not published in peer-reviewed form, reportedly showed no significant change in serum creatinine versus placebo. The absence of peer review and the lack of access to individual patient data make this finding difficult to interpret. Renal endpoints were not pre-specified.

Renal Risk Factors That Prescribers Must Consider

Even without a characterized renal toxicity signal, several patient-level factors should shape prescribing decisions for AOD-9604.

Baseline CKD and Peptide Accumulation

Patients with CKD stage 3b or worse (eGFR <45 mL/min/1.73 m²) have reduced proximal tubule catabolism of small peptides. The National Kidney Foundation's KDOQI guidelines recommend caution with any renally cleared peptide or protein drug in patients with eGFR <45 mL/min/1.73 m², advising dose adjustment or avoidance until clearance data are available. [9] Because AOD-9604 clearance data in humans with CKD do not exist, the conservative approach is to avoid use in this population.

Patients with CKD stage 4 or 5 (eGFR <30 mL/min/1.73 m²) should not receive AOD-9604 outside a formal research protocol.

Diabetic Nephropathy and the GLP-1 Comparison

Many patients seeking AOD-9604 for adipose modulation also carry a diagnosis of type 2 diabetes. In that context, prescribers often consider AOD-9604 alongside or instead of GLP-1 receptor agonists. The renal data for GLP-1 agents are far more strong. The CREDENCE trial (N = 4,401) showed canagliflozin reduced the composite of renal or cardiovascular death by 30% in patients with type 2 diabetes and albuminuric CKD. [10] The FLOW trial (N = 3,533) demonstrated that semaglutide 1 mg weekly reduced the primary kidney composite endpoint by 24% versus placebo (HR 0.76, 95% CI 0.66 to 0.88, P<0.001) in patients with type 2 diabetes and CKD. [11]

AOD-9604 has no comparable data. Choosing it over agents with demonstrated renal benefit in diabetic nephropathy patients is not defensible with current evidence.

Concomitant Nephrotoxic Agents

Patients using AOD-9604 alongside NSAIDs, calcineurin inhibitors, or IV contrast agents face compounded renal risk. Because AOD-9604's renal handling is unknown, the margin for additional nephrotoxic insult cannot be estimated. Prescribers should document baseline eGFR and urine albumin-to-creatinine ratio (UACR) before initiating AOD-9604 and repeat both at 90 days.

The Theoretical Renal Protection Hypothesis

Some practitioners cite AOD-9604's lipid-lowering and anti-inflammatory potential as indirect renal protection. The reasoning runs: adipose reduction lowers visceral fat mass, which reduces adipokine-driven renal inflammation, which slows CKD progression. This is a three-step inference with no direct supporting data for AOD-9604.

Adipose Reduction and Kidney Function

Obesity is an independent risk factor for CKD progression. A 2021 meta-analysis in JASN (pooled N = 62,000 across 19 cohorts) found that each 5-unit increase in BMI raised the risk of incident CKD by 23% (RR 1.23, 95% CI 1.18 to 1.29). [12] Weight loss interventions that reduce BMI by 5% or more produce measurable reductions in proteinuria and glomerular hyperfiltration in obese CKD patients.

If AOD-9604 produces the approximately 10 to 15% body fat reduction suggested by Heffernan's obese mouse model [1], an indirect renal benefit through adipose reduction is biologically plausible. The magnitude, however, cannot be extrapolated from mouse data, and no human weight-loss outcome data for AOD-9604 meet the quality threshold needed to quantify that effect.

Anti-Inflammatory Peptide Effects

Some GH-related peptides modulate NF-kB signaling and reduce pro-inflammatory cytokine production in vitro. A 2019 study in Peptides demonstrated that C-terminal GH fragments reduced TNF-alpha secretion in LPS-stimulated macrophages by approximately 35% at pharmacological concentrations. [13] AOD-9604 was not the specific fragment tested in that study, but the structural overlap raises a plausible mechanistic parallel.

Whether anti-inflammatory signaling at the macrophage level translates into reduced renal interstitial inflammation in vivo, and at what dose, is unknown.

Monitoring Protocol for AOD-9604 Prescribers

Given the absence of human renal safety data, the HealthRX medical team recommends the following minimum monitoring framework for any patient receiving compounded AOD-9604.

Baseline Assessment

Before the first dose, obtain serum creatinine with calculated eGFR using the 2021 CKD-EPI creatinine equation (the race-free version endorsed by the National Kidney Foundation and ASN joint task force [9]), a spot urine UACR, a comprehensive metabolic panel, and a fasting lipid panel. Document the prescribing indication, compounding pharmacy lot number, and the dose in milligrams per kilogram.

Patients with eGFR <45 mL/min/1.73 m² should not start AOD-9604 without documented informed consent addressing the absence of renal safety data and a plan for more frequent monitoring (every 4 weeks rather than 90 days).

Ongoing Monitoring

Repeat eGFR and UACR at 90 days and at 6 months. A decrease in eGFR of 10 mL/min/1.73 m² or more from baseline, or a doubling of UACR from baseline, should prompt immediate discontinuation and nephrology referral. These thresholds align with the FDA's 2022 guidance on surrogate endpoints for CKD drug trials, which identifies a 30 to 40% sustained eGFR decline as a clinically meaningful signal but recommends earlier intervention in non-approved-drug contexts. [14]

Discontinuation Criteria

Stop AOD-9604 immediately if the patient develops any of the following: eGFR decline of more than 10 mL/min/1.73 m² from baseline confirmed on repeat testing 2 weeks apart, new-onset UACR above 300 mg/g, signs of acute kidney injury by KDIGO criteria (serum creatinine rise of 0.3 mg/dL within 48 hours or 1.5x baseline within 7 days [9]), or any systemic hypersensitivity reaction that could indicate immune complex deposition.

Comparing AOD-9604 to Agents With Established Renal Profiles

Prescribers weighing AOD-9604 for patients who carry metabolic disease with renal involvement should understand where it sits relative to agents that have completed renal endpoint trials.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy) reduced cardiovascular death, non-fatal MI, and non-fatal stroke by 20% in SELECT (N = 17,604, median follow-up 34.2 months). [15] The FLOW trial confirmed direct renal benefit for semaglutide 1 mg in CKD patients. [11] Liraglutide showed a 22% reduction in new-onset macroalbuminuria in LEADER (N = 9,340). [16] These are completed, peer-reviewed, regulatory-grade trials.

AOD-9604 has none of that evidence. In a patient with type 2 diabetes and stage 3 CKD, prescribing AOD-9604 over a GLP-1 agent with proven renal benefit requires explicit justification.

Tesamorelin

Tesamorelin (Egrifta) is an FDA-approved GHRH analog. Unlike full-length GH, tesamorelin raises IGF-1 modestly (by approximately 35% from baseline at 2 mg/day over 26 weeks in HIV-associated lipodystrophy trials). [17] Its renal effects have been studied; no significant change in eGFR or proteinuria was found in the Phase III trials. Tesamorelin's renal data, limited as they are, still exceed what exists for AOD-9604.

Clinical Summary and Prescriber Decision Framework

The question, "Does AOD-9604 protect or harm the kidneys?" cannot be answered with the current evidence base. The mechanistic argument for a favorable renal profile relative to full-length GH is plausible: no GHR activation means no GH-driven glomerular hyperfiltration, and no IGF-1 elevation removes one additional pro-fibrotic signal. Those are meaningful theoretical advantages.

The argument for active renal protection, the claim that AOD-9604 reduces kidney disease risk, has no supporting clinical trial data. Zero published human studies have measured renal endpoints as a primary or secondary outcome.

Prescribers should treat AOD-9604 as renally uncharacterized. The absence of a known harm is not the same as confirmed safety. Patients with established CKD, particularly those with eGFR <45 mL/min/1.73 m² or UACR above 30 mg/g at baseline, should receive only agents with established renal safety profiles unless enrolled in a formal trial.

For patients without CKD, prescribers who choose to use AOD-9604 should document baseline renal function, repeat eGFR and UACR at 90 days, and discontinue at the first sign of a 10 mL/min/1.73 m² or greater sustained eGFR decline from baseline.